Weight Loss Results
Wegovy Before and After Results: Expected Weight Loss Timeline
Quick Answer: Clinical trial data from STEP UP shows that patients on Wegovy (semaglutide 7.2 mg) lose an average of approximately 5–7% of body weight within the first three months, around 12% by six months and approximately 19–21% by 72 weeks. In absolute terms, a patient starting at 115 kg could expect to lose approximately 8 kg by month three, 15 kg by six months and up to 23 kg within 72 weeks. Results vary depending on starting weight, adherence, diet and activity level.~19–21%average weight loss at 72 weeks (STEP UP, 7.2 mg)
~5–7%typical weight loss at 3 months
>9 in 10STEP UP participants achieved at least 5% weight loss
The Evidence
Wegovy Clinical Trial Results: The Evidence Base
The weight loss data for Wegovy 7.2 mg comes from the STEP UP (Semaglutide Treatment Effect in People with Obesity at a higher dose) clinical trial, a randomised, controlled, phase 3b trial involving adults with obesity across multiple countries. This trial builds on the STEP programme that led to MHRA approval and NICE recommendation (TA875) in the UK.
The STEP UP trial enrolled adults with a BMI of 30 or above (or 27 or above with at least one weight-related comorbidity) and no type 2 diabetes. Participants received either semaglutide 7.2 mg once weekly or placebo alongside a reduced-calorie diet and increased physical activity. At 72 weeks, the semaglutide 7.2 mg group achieved an average weight loss of 20.7% of body weight (trial product estimand), compared with 2.4% in the placebo group.
STEP UP: Headline Outcomes at 72 Weeks
What the Trial Data Means in Practice
Clinical trial results represent population averages across thousands of participants with diverse starting weights, metabolic profiles and levels of adherence. Individual results will vary. Some patients achieve substantially more than the trial average; others achieve less. Understanding that 19–21% is the central range — not a guaranteed outcome — is important for setting realistic expectations before starting treatment.
| Outcome Measure | Semaglutide 7.2 mg | Placebo |
|---|---|---|
| Mean weight loss at 72 weeks | ~20.7% (trial product estimand) | ~2.4% |
| Weight loss of ≥5% | >9 out of 10 participants | 32% of participants |
| Weight loss of ≥10% | 69% of participants | 12% of participants |
| Weight loss of ≥15% | 50% of participants | 5% of participants |
| Weight loss of ≥20% | 32% of participants | 2% of participants |
| Mean absolute weight reduction | ~23.2 kg | ~2.7 kg |
Important context: Clinical trial results represent population averages. Individual results will vary based on starting weight, dose reached, diet quality, activity level and metabolic health. The 19–21% figure is the central estimate — half of patients achieved more, half achieved less.
Month by Month
Month 1 Wegovy Results: What to Expect
The first month of Wegovy treatment is the 0.25 mg tolerability phase. At this dose, semaglutide is not yet at its full therapeutic concentration, and significant weight loss is not expected or clinically intended. Despite this, many patients notice early changes that serve as encouraging signals.
Typical Weight Loss in Month 1
Most patients lose between 1 and 4 kg in their first month of Wegovy, depending on starting weight, dietary changes and activity level. Patients with higher starting weights tend to see larger absolute losses in the early weeks. Some patients report minimal weight loss in month one, which is entirely normal given the sub-therapeutic starting dose.
More noticeable than the number on the scales is often the change in appetite. Many patients describe a meaningful reduction in hunger, food cravings and portion sizes within the first two weeks — even at 0.25 mg. This appetite suppression is the drug working as intended and typically translates into weight loss as it accumulates over successive weeks.
Beyond the Scales: Early Physical Changes
Some patients notice reduced bloating and changes in body composition even before significant scale weight is lost. Clothing may feel marginally looser, and patients with a history of binge eating or compulsive snacking often report the most dramatic early subjective changes — describing a sense of food no longer having the same grip on their daily life.
Month 1 Reality Check: If you have lost only 1–2 kg in your first month, this is normal and does not indicate the medication is not working. The 0.25 mg dose is a tolerability phase. The significant weight loss associated with Wegovy comes with the higher doses reached during and after escalation.
Month 3 Wegovy Results: The First Milestone
Three months is the first clinically meaningful milestone for Wegovy patients. By this point, most patients will have reached or be approaching the 1.0 mg dose, appetite suppression is well established, and cumulative weight loss begins to reflect the drug's full early effect.
Typical Weight Loss at 3 Months
Clinical trial data and real-world evidence suggest that most patients lose between 5% and 7% of their starting body weight within the first three months of Wegovy treatment. For a patient starting at 100 kg, this equates to 5–7 kg. For a patient starting at 120 kg, it may be closer to 6–9 kg. Approximately 50% of patients achieve 5% or more weight loss by week 12 — a commonly used clinical benchmark associated with meaningful improvements in blood pressure, blood glucose, cholesterol and joint load.
Body Composition Changes at 3 Months
By month three, patients on Wegovy are typically eating significantly less than before treatment. Without adequate protein intake and some form of physical activity, a proportion of weight loss at this stage may come from lean muscle mass rather than exclusively from fat. This is why maintaining a protein intake of at least 1.2 g per kilogram of body weight is routinely recommended for patients on GLP-1 receptor agonists.
How Quickly Does Wegovy Work?
Wegovy begins working within the first week of injection — GLP-1 receptor activity increases from the first dose. However, the clinical effect on weight accumulates over months rather than days. Patients who expect dramatic results in the first two to four weeks are likely to be disappointed. The drug's mechanism is gradual and cumulative. This is by design: sustainable weight loss achieved through appetite regulation is more physiologically durable than rapid loss achieved through severe calorie restriction.
Month 6 Wegovy Results: Significant Progress
Six months into Wegovy treatment, most patients have been at or near the 7.2 mg maintenance dose for approximately two months. This is where the drug's full therapeutic effect is most clearly visible, and where patients typically begin to see the changes that motivate long-term continuation.
Typical Weight Loss at 6 Months
Analysis of STEP trial data at approximately 28 weeks (close to six months) suggests average weight loss in the range of 12–15% of baseline body weight. For a 100 kg patient, this represents 12–15 kg of weight loss. For a 130 kg patient, losses of 16–20 kg are consistent with this range. A proportion of patients — around one in three — will have achieved greater than 10% weight loss by this point.
Visible and Health Improvements at 6 Months
Six months of consistent Wegovy treatment typically produces changes that extend well beyond weight loss alone. Patients frequently report improvements in:
- Blood pressure — reductions of 5–10 mmHg in systolic blood pressure are common
- Blood glucose — fasting glucose and HbA1c improvements in patients with pre-diabetes or type 2 diabetes
- Joint pain — reduced load through knees, hips and ankles as weight decreases
- Sleep quality — particularly in patients with weight-related sleep apnoea
- Energy levels — increased stamina and reduced fatigue as weight decreases and eating habits stabilise
- Mood and self-perception — improved confidence and reduced food-related anxiety reported by many patients
Timeline
Wegovy Weight Loss Timeline at a Glance
Results by Starting Weight at 72 Weeks
Month 1~2–3%~2–4 kgEarly signals
Month 3~5–7%~5–9 kgNoticeable change
Month 6~12%~12–17 kgStrong progress
Week 72~19–21%~14–23 kgFull effect
| Starting Weight | 5% Loss | 10% Loss | 20% Loss (avg) | 25% Loss |
|---|---|---|---|---|
| 80 kg | 4 kg → 76 kg | 8 kg → 72 kg | 16 kg → 64 kg | 20 kg → 60 kg |
| 100 kg | 5 kg → 95 kg | 10 kg → 90 kg | 20 kg → 80 kg | 25 kg → 75 kg |
| 120 kg | 6 kg → 114 kg | 12 kg → 108 kg | 24 kg → 96 kg | 30 kg → 90 kg |
| 140 kg | 7 kg → 133 kg | 14 kg → 126 kg | 28 kg → 112 kg | 35 kg → 105 kg |
Maximising Results
Factors That Affect Wegovy Results
Wegovy produces clinically significant weight loss in the vast majority of patients who complete treatment, but individual outcomes vary considerably. Understanding the factors that influence results helps patients maximise their own response to treatment.
Starting Weight and BMI
Patients with higher starting weights tend to lose greater absolute amounts of weight, though percentage weight loss is broadly consistent across weight categories. A patient starting at 140 kg who achieves 15% loss will lose 21 kg; a patient starting at 90 kg achieving the same percentage loses 13.5 kg. Both outcomes are clinically significant. Patients closer to the lower BMI eligibility threshold (27–30) may experience a somewhat slower weight loss trajectory.
Diet Quality
Wegovy significantly reduces appetite, but it does not alter what patients choose to eat. Patients who use the reduced appetite as an opportunity to improve diet quality — increasing protein and fibre intake, reducing ultra-processed foods and added sugars — consistently achieve better outcomes than those who continue previous eating patterns at a smaller volume. The drug creates the conditions for better choices; the patient still needs to make them.
Physical Activity
Exercise does not dramatically accelerate weight loss on Wegovy for most patients, but it plays a critical role in body composition. Patients who incorporate resistance training or consistent aerobic activity preserve more lean muscle mass during weight loss, resulting in better metabolic outcomes and a more toned physical appearance at the same scale weight. The STEP 3 trial, which combined semaglutide with intensive behavioural therapy including physical activity support, achieved slightly higher average weight loss than STEP 1.
Adherence to the Dose Schedule
Consistent weekly injection without missed doses is associated with better outcomes. Multiple missed doses reduce the therapeutic concentration of semaglutide in the bloodstream, diminishing appetite suppression and slowing weight loss. Patients who travel frequently, have irregular schedules or are prone to forgetting weekly tasks should plan in advance how to maintain treatment consistency.
Metabolic Factors
Underlying metabolic health affects the rate of weight loss on Wegovy. Patients with hypothyroidism (especially if undertreated), polycystic ovary syndrome (PCOS), insulin resistance or type 2 diabetes may find weight loss progresses more slowly, particularly in the early months. These conditions do not prevent Wegovy from working, but they may require additional clinical management alongside treatment.
Sleep and Stress
Sleep deprivation and chronic psychological stress both impair the hormonal environment for weight loss — elevating cortisol, disrupting hunger hormones and promoting fat storage, particularly around the abdomen. Patients who address sleep quality and stress management alongside Wegovy treatment consistently report better outcomes. This is not unique to semaglutide — it applies to any weight loss intervention.
Illustrative Examples
Typical Wegovy Weight Loss Examples
The following examples are based on STEP UP clinical trial averages at the 7.2 mg dose level and are illustrative rather than individual patient accounts.
Example A: Starting weight 95 kg, BMI 33
3 months: 88 kg (lost ~7 kg, ~7.4%)
6 months: 83 kg (lost ~12 kg, ~12.6%)
72 weeks: 76 kg (lost ~19 kg, ~20%)
Example B: Starting weight 115 kg, BMI 38
3 months: 107 kg (lost ~8 kg, ~7%)
6 months: 100 kg (lost ~15 kg, ~13%)
72 weeks: 92 kg (lost ~23 kg, ~20%)
Example C: Starting weight 130 kg, BMI 42
Based on STEP UP semaglutide 7.2 mg trial average outcomes. Individual results will vary.
Common Mistakes That Affect Wegovy Results
3 months: 121 kg (lost ~9 kg, ~6.9%)
6 months: 113 kg (lost ~17 kg, ~13%)
72 weeks: 104 kg (lost ~26 kg, ~20%)
| Common Mistake | Why It Slows Results | What to Do Instead |
|---|---|---|
| Eating through nausea | Forcing food despite nausea overrides the satiety signal, increasing calorie intake above the reduced level the drug is trying to establish. | Listen to appetite signals — eat only when genuinely hungry and stop when comfortable, not full. |
| Choosing high-calorie liquids | Liquid calories — alcohol, sugary drinks, smoothies, full-fat lattes — bypass satiety signals and are easy to overconsume despite reduced solid food appetite. | Stick to water, herbal teas and low-calorie drinks. Minimise alcohol entirely during active weight loss. |
| Skipping meals then bingeing | Extended fasting followed by eating can trigger compensatory eating, undermining the steady calorie reduction Wegovy is designed to create. | Eat small, regular meals to maintain stable energy and work with the drug's mechanism. |
| Not prioritising protein | Low protein intake during rapid weight loss leads to muscle loss, a reduced metabolic rate and a less favourable body composition at the target weight. | Aim for 1.2–1.5 g of protein per kg of body weight daily from lean meat, fish, eggs, legumes or dairy. |
| Stopping treatment early | Evidence consistently shows substantial weight regain within 12 months of stopping. STEP 4 demonstrated approximately two-thirds of lost weight regained. | Treat Wegovy as a long-term tool. Discuss any planned discontinuation with your prescribing pharmacist first. |
| Missing injections | Multiple missed doses reduce semaglutide blood levels and weaken appetite suppression, slowing weight loss. | Set a weekly reminder. If a dose is missed by more than 5 days, skip it and resume on the usual day. |
Key Questions
Key Questions Answered
How much weight can you lose on Wegovy?
Clinical trial data from the STEP UP study shows that patients on semaglutide 7.2 mg lose an average of 20.7% of their body weight over 72 weeks. In practical terms, this equates to approximately 20 kg for a 100 kg patient over 18 months of treatment. More than 9 out of 10 participants lost 5% or more; approximately 1 in 3 lost 25% or more. These are population averages — individual outcomes depend on starting weight, diet, activity level, metabolic health and adherence to treatment.
What results can I expect after 3 months on Wegovy?
At three months, most Wegovy patients have lost between 5% and 7% of their starting body weight. For someone starting at 100 kg, this means approximately 5–7 kg. For someone starting at 120 kg, closer to 6–9 kg. The three-month mark coincides with dose escalation toward the maintenance dose — the point at which appetite suppression is most pronounced before the body has fully adapted. Patients who have made dietary improvements alongside treatment tend to see results at the higher end of this range. A loss of 5% or more at three months is a clinically meaningful outcome associated with measurable health improvements.
Does Wegovy work quickly?
Wegovy begins producing biological effects within the first week of injection, with GLP-1 receptor activity increasing from the first dose. Most patients notice a reduction in appetite and food cravings within two to three weeks. However, significant weight loss is a gradual process — the average patient loses 2–4 kg in the first month and around 5–7% of body weight by three months. The most dramatic results emerge between months three and twelve as the dose reaches and sustains the maintenance level. Wegovy is not a rapid weight loss solution; it is a long-term treatment for chronic weight management that produces meaningful, sustained results when used consistently.
FAQs
Frequently Asked Questions: Wegovy Results
Most patients lose between 1 and 4 kg in the first month of Wegovy treatment, though individual variation is significant. Month one is the 0.25 mg tolerability phase, so results are modest by design. Weight loss accelerates from months two to five as the dose escalates.
Most patients lose between 5% and 7% of their starting body weight within the first three months. For a 100 kg patient this means approximately 5–7 kg. For a 120 kg patient, closer to 6–9 kg. Three months coincides with escalation toward the maintenance dose — appetite suppression is still building.
Wegovy begins producing biological effects within the first week — GLP-1 receptor activity increases from the first dose. Most patients notice reduced appetite and food cravings within two to three weeks. Significant weight loss builds gradually across the escalation schedule, with the most rapid reductions typically between months three and twelve.
Yes — a 5% reduction in body weight from baseline is a clinically meaningful threshold associated with measurable improvements in blood pressure, blood glucose and cardiovascular risk markers. Achieving 5% loss by month three is consistent with clinical trial averages and is a positive early indicator.
Weight loss typically slows as patients approach their new metabolic equilibrium, usually after six to twelve months of maintenance. A weight loss plateau does not mean treatment has failed — it means the body is adapting. Dietary review and increased physical activity often help overcome plateaus.
Approximately one in three participants in the STEP UP trial achieved 20% or more weight loss at 72 weeks on semaglutide 7.2 mg. This is achievable but not guaranteed. Higher starting weights, consistent adherence and good dietary practices are associated with greater weight loss.
The STEP 4 trial showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within 12 months. This reflects the chronic nature of obesity — Wegovy manages the condition while being taken. Stopping should be a planned clinical decision made with your prescribing pharmacist.
Exercise significantly improves body composition outcomes on Wegovy — particularly resistance training, which helps preserve lean muscle mass during active weight loss. It has a modest additional impact on total weight lost but a meaningful impact on the quality of that weight loss and longer-term metabolic health.
Wegovy is considered to be working if you have lost at least 5% of your starting body weight by week 16 of treatment, in line with clinical assessment criteria. Most patients notice appetite reduction much earlier than this — within two to four weeks of starting — which is the first sign that the medication is active.
Yes. The STEP 3 trial, which combined semaglutide with a structured low-calorie diet phase, achieved higher average weight loss than lifestyle advice alone. Dietary quality amplifies Wegovy's effect. Patients do not need to follow a rigid low-calorie diet, but attention to food choices significantly improves outcomes.
Clinical trial data shows broadly similar weight loss outcomes for men and women on Wegovy, though starting weight, metabolic profile and hormonal factors can produce individual variation. Women with PCOS or perimenopausal hormonal changes may find weight loss progresses somewhat differently — worth discussing with your prescribing clinician.
It is not possible to predict individual Wegovy outcomes with precision. The 19–21% average from STEP UP is a population mean — half of patients lost more, half lost less. Starting weight, metabolic health, diet quality, activity level and adherence all influence where on that spectrum an individual patient falls.
Ready to Start Your Wegovy Journey?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment · Superintendent Pharmacist: Palvinder Deol · Trustpilot 4.8 ★
Check Your Eligibility →
Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;S2213–8587(25):00226–8. | Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as Adjunct to Intensive Behavioral Therapy (STEP 3). JAMA. 2021;325(14):1403–1413. | Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414–1425. | NICE TA875. Semaglutide for managing overweight and obesity. March 2023. | Novo Nordisk. Wegovy Summary of Product Characteristics. 2023/2025. | GPhC. Standards for registered pharmacies. 2023. gphc.org.uk | Happy Pharmacy (GPhC No. 9012585). Educational purposes only — not a substitute for individualised clinical assessment.